Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
This study will evaluate the efficacy, safety, tolerability of imatinib in the neoadjuvant treatment (pre-operatory) of patients with GIST. It will also evaluate the potential of imatinib to convert a tumor from inoperable to operable.
Gastrointestinal Stromal Tumors
DRUG: imatinib mesylate
Objective response using the RECIST criteria, 16 weeks
Progression free survival, 16 weeks|Time and duration of response, 16 weeks|Time to treatment failure, 16 weeks|Overall survival, 16 weeks
This study will evaluate the efficacy, safety, tolerability of imatinib in the neoadjuvant treatment (pre-operatory) of patients with GIST. It will also evaluate the potential of imatinib to convert a tumor from inoperable to operable.